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Background
Psoriatic arthritis is a chronic inflammatory joint disease, associated with psoriasis [1-4], 
and is “associated with increased mortality from cardiovascular disease” [5]. Two recent sys-
tematic reviews investigated its prevalence at an international level and in Italy [6,7]. Scotti 
and colleagues [6] evaluated epidemiological studies worldwide (referred to the European 
context, Northern and Southern American context and Asian context) and reported a pooled 
prevalence of psoriatic arthritis of 133 cases every 100,000 subjects (with a high between-
study heterogeneity), with study prevalence rates ranging from 20 cases every 100,000 sub-
jects (in a study on the Swedish context referred to 1961-1963) [8] to 670 cases every 100,000 
subjects (in a study on the Norwegian context referred to 2006-2008) [9]. Prignano and col-
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aBstract
BACKGROUND: The management of psoriatic arthritis requires competencies in the fields of both rheumatology and 
dermatology, and a multidisciplinary approach.
AIM: To propose an effective pathway for the diagnosis, monitoring and treatment of psoriatic arthritis in the Italian con-
text, and to assess its organizational impact on the Regional Health Service of Lombardy Region.
METHODS: The analysis was performed through interviews conducted with two key opinion leaders in the areas of derma-
tology and rheumatology. The current pathway of patients who present symptoms that might be related to psoriatic arthritis 
was defined and an optimized pathway was then proposed on the basis of the clinical practice, considering the implementa-
tion of a dermatology and rheumatology shared outpatient service. The organizational impact of the optimized pathway was 
then assessed from both the hospital and that of the Regional Health Service of Lombardy Region perspectives.
RESULTS: The implementation of the service would have a positive impact on patients’ experience, improving the quality 
of the service provided, thanks to the multidisciplinary approach adopted, limiting the patients’ resources needed for the 
diagnosis, reducing the number of visits and time loss. The optimized pathway, therefore, would have a limited impact on 
the marketing mix, while potentially improving patients satisfaction, increasing the possibility of patients’ retention. To 
successfully implement the dermatological and rheumatologic multidisciplinary service, a precise communication strategy 
is mandatory.
CONCLUSIONS: The optimized pathway for the diagnosis and management of psoriatic arthritis proposed would have a 
limited organizational impact at both hospital and Regional Health Service levels, while leading to theoretical benefits in 
terms of a prompt diagnosis of the pathology.
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prevalence of psoriatic arthritis in two sample populations referred to Marche Region (central 
Italy, among adults with ≥ 18 years) and Chiavari (a municipality located in Liguria Region, 
Northern Italy, among adults with ≥ 16 years). The first study, referred to 2004, assessed a 
prevalence of 0.42% [10,11], while the latter, referred to 1991-1992, assessed a prevalence 
of 0.09% [12].
The management of psoriatic arthritis requires competencies in the fields of both rheuma-
tology and dermatology, and a multidisciplinary approach. It is therefore important to imple-
ment clinical pathways that allow an efficient management of patients, shortening the time 
to diagnosis. A timely diagnosis of psoriatic arthritis, in fact, might lead to a prompt therapy 
start, slowing the disease progression.
The aim of the present analysis is to propose an effective pathway for the diagnosis, moni-
toring and treatment of psoriatic arthritis in the Italian context, and to assess its organizational 
impact on the Regional Health Service of Lombardy Region.
Methods
The analysis was performed through interviews conducted with two key opinion leaders 
in the areas of dermatology and rheumatology: the director of the Dermatology ward, and 
the director of the Rheumatology and Clinical Immunology ward of the Clinical Institute 
Humanitas located in Rozzano, Milan.
The current pathway of patients who present symptoms that might be related to psoriatic 
arthritis was defined considering the first access to primary care services, specialist visits, 
health services for the diagnosis of the pathology, outpatients activities for patients’ monitor-
ing and treatments. Three typologies of psoriatic arthritis were considered: predominantly 
dermatological (in which symptoms are mainly related to the dermatological field), predomi-
nantly rheumatologic (axial) and predominantly rheumatologic (peripheral).
An optimized pathway was then proposed on the basis of the clinical practice of the 
aforementioned key opinion leaders, considering the implementation of a dermatology and 
rheumatology shared outpatient service, to improve patients’ experience and the efficiency of 
resources allocation.
The organizational impact of the optimized pathway was then assessed from both hospital 
and Regional Health Service of Lombardy Region perspectives through the use of the Health 
Technology Assessment (HTA) Core Model® developed by the European Network for Health 
Technology Assessment (EUnetHTA), version 3.0 [13]. Among the 9 domains considered 
within the model (Health problem and current use of technology; Description and technical 
characteristics of technology; Safety; Clinical effectiveness; Costs and economic evaluation; 
Ethical analysis; Organizational aspects; Patients and Social aspects; Legal aspects) [13] the 
organizational aspect is declined into 5 items: the health delivery process, the structure of 
health care system, process-related costs, management, and culture. All the issues considered 
for each item were analyzed and discussed with the key opinion leaders involved, to identify 
the consequences of the implementation of the optimized pathway.
results
The two pathways of patients with symptoms that might be related to psoriatic arthritis are 
composed by a diagnostic phase and a monitoring/treatment phase.
Currently adopted pathway
The first step of the pathway consists in a general practitioner visit. The patient might then 
be addressed to a dermatological specialist visit. If the dermatologist detects symptoms that 
might be related to psoriatic arthritis, a rheumatologic specialist visit is prescribed. If the sus-
pect of psoriatic arthritis is confirmed, the following diagnostic activities are prescribed: sedi-
mentation velocity, rheumatoid factor, cyclic citrullinated peptide antibody, interferon gamma 
release assay test, hepatitis B virus antigen, hepatitis B virus antibodies, hepatitis C virus an-
tibodies, ultrasound of muscles and tendons (for each painful area). Once the aforementioned 
Outpatient activity





Specialist visit 4 4
Complete blood test 4 4
Uric acid 4 4
C-reactive protein 4 4
Glucose test 4 4
Transaminases 4 4
X-rays of the hands and wrists 1 1
Magnetic resonance of the hip 0.252 0.53
Creatinine 4 4
Alanine aminotransferase 4 4
Vitamin D 1 1
Table I. Annual monitoring scheme for psoriatic arthritis
1 Axial or peripheral
2 Every 4 years
3 Every 2 years
Figure 1. Currently adopted pathway of patients with symptoms potentially related to psoriatic arthritis
DMARD = conventional synthetic Disease Modifying Anti-Rheumatic Drugs; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs; PASI = Psoriasis Area 
Severity Index; PsA = Psoriatic Arthritis
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tests are performed, a second dermatological specialist visit is performed to confirm or not 
the psoriatic arthritis diagnosis. This first part of the pathway can be considered in a specular 
way considering as a first specialist visit a rheumatologic visit instead of a dermatologic one.
Based on the results of the tests, an adequate therapeutic pathway will be set up consider-
ing the type of psoriatic arthritis diagnosed: predominantly dermatological, predominantly 
rheumatologic – axial or predominantly rheumatologic – peripheral. In case the pathology is 
not diagnosed, the same tests will be repeated after 12 months. A common monitoring scheme 
will be also implemented, considering the activities reported in Table I.
The schematization of the currently adopted pathway is presented in Figure 1, along with 
the therapeutic sequences per type of psoriatic arthritis diagnosed to the patient, in terms of 
treatment typology.
The optimized clinical pathway is characterized by the availability of a dermatology 
and rheumatology shared outpatient service, that allow the performance of multidisci-
plinary specialist visits. The patient might approach the service after a primary care visit 
with his/her general practitioner, who might observe symptoms related to psoriasis and/or 
arthritis and can prescribe a dermatological or rheumatologic specialist visit. The special-
ist visit might be performed at a territorial level by a dermatologist or by a rheumatologist 
(based on the symptoms observed by the general practitioner) and, if symptoms related to 
psoriatic arthritis are observed, a specialist visit to the shared outpatient service might be 
prescribed. Patients might avoid the general practitioner visit, performing a private spe-
cialist visit before being addressed to the shared outpatient service. Within this service, a 
dermatological and rheumatologic multidisciplinary visit will be performed to assess the 
appropriate diagnostic pathway for psoriatic arthritis (that might consider the activities 
reported in Table I). Based on the tests results, an adequate therapeutic pathway will be set 
up, as in the actual pathway, along with monitoring activities. The optimized pathway is 
represented in Figure 2.
Organizational impact of the optimized pathway
The results of the organizational impact analysis are reported considering the main topics 
of the EUnetHTA Core Model® (Version 3.0).
The health delivery process will be partially influenced at a hospital level due to the fact 
that patients with suspected psoriatic arthritis will be visited within the multidisciplinary out-
patient service, requiring the identification of opening days and hours, and of preferential slots 
to perform diagnostic tests to the patients referring to the service. The processes related to the 
booking of visits and back office activities would not be affected by the service.
The first step of the process, represented by territorial primary care and specialist vis-
its, would allow only patients with symptoms that might be related to psoriatic arthritis 
to access the multidisciplinary service. The service would allow an increase in the effi-
ciency of the diagnostic process, avoiding a step (in terms of specialist dermatological or 
rheumatologic visit), reducing the time needed to confirm the diagnosis. The visit in the 
multidisciplinary service might be performed by a specialist, with the possibility to request 
an immediate consultation with a dermatologist or a rheumatologist, optimizing the use of 
human resources.
No particular involvement for patients and/or caregivers is expected. The optimized path-
way might require a reduced number of visits, with the possibility to identify timely symp-
toms that might be related to psoriatic arthritis. This comprehensive management of the pa-
tient might have positive consequences for the hospital, in terms of patient’s retention (defined 
as the ability of the service/hospital to maintain a long term relationship with the patient).
No specific training would be required for the hospital specialists for the implementation 
of the service. Specific training might be necessary at a primary care level, to instruct general 
practitioner concerning the symptoms related to psoriatic arthritis, that should be considered 
to prescribe a specialist visit to diagnose the pathology, and to present them the optimized 
pathway.
A specific communication activity to inform of the availability of the multidisciplinary 
service should be addressed to general practitioners and territorial pharmacists. Furthermore, 
communication to patients’ associations should be performed to inform on the availability of 
the service within the optimized pathway.
No peculiar quality assurance and monitoring systems should be activated beside those 
already activated within the hospitals that will activate the multidisciplinary service.
From a Regional Health Service perspective, no differences would be assessed consider-
ing the health delivery process.
Concerning the structure of the health care system topic, a higher degree of centralization 
or de-centralization would not influence the implementation of the optimized pathway.
The processes that would allow patients to access the optimized pathway are those de-
scribed upon, in terms of communication activity with professionals within primary care 
service. The already existing processes would allow patients to access the multidisciplinary 
service.
In terms of process-related costs, those related with the implementation of the optimized 
pathway would depend on each hospital that will activate it, and are related to the physical 
structure in which the visits will be performed: room, furniture, waiting room. These might be 
already available within the hospital. Furthermore, considering the fact that the visits of the 
multidisciplinary service will be programmed, it would be possible to use already available 
spaces, used to perform dermatological or rheumatologic specialist visits, identifying time 
slots to be used for these visits.
The optimized pathway would not reduce the diagnostic activity performed in absolute 
terms, however it would reduce the time to diagnosis. A timely start of psoriatic arthritis 
Figure 2. Proposed optimized pathway for patients with symptoms potentially related to psoriatic arthritis
DMARD = conventional synthetic Disease Modifying Anti-Rheumatic Drugs; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs; PASI = Psoriasis Area 
Severity Index; PsA = Psoriatic Arthritis
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therapy might lead to benefits to the patients in terms of therapy effectiveness and quality of 
life (considering the negative effects of psoriatic arthritis on this parameter) [14,15].
The main impact on a hospital budget might be related to the identification and furnishing 
of the rooms to be dedicated to the multidisciplinary service, however, depending on each 
hospital activating the service, it is difficult to estimate the potential budget impact, that might 
be equal to 0 in case of already available spaces. The back office activity related to the book-
ing of the service would be the same already available within each hospital.
If properly perceived at a territorial level and by patients, a potential effect of the opti-
mized pathway might be the increase of specialist visits within the hospital.
From the Regional Health Service perspective, the multidisciplinary service might ac-
celerate the diagnostic phase of the pathway, with positive consequences in terms of prompt 
therapy start, as described upon, reducing the progress of the pathology with positive conse-
quences on the health services delivered to the patient.
The theoretical increase in the number of diagnosis in the short/medium term, might lead 
to an increase of health expenditures, due to the increased number of patients starting psoriatic 
arthritis therapies, being compensated by the improved clinical conditions of patients with a 
hypothetical reduction of direct medical costs in a long term time horizon, in terms of reduced 
hospitalizations, outpatient activities and drugs.
Concerning the “management” topic, no peculiar problems are forecasted in terms of safe-
ty and risk management. To ensure the access to the multidisciplinary service, a tight coordi-
nation with territorial specialists will be necessary. This is of high importance, considering the 
aforementioned role of general practitioners, dermatologists and rheumatologists operating 
within territorial health centers, whom will address the patients on the base of the symptoms 
assessed during the visits.
No critical points are envisaged in cultural terms in the acceptance of the multidisciplinary 
service by patients, for whom an increase in the satisfaction for the services delivered might 
be observed due to the reduced time to diagnosis. The personnel of each hospital in which 
the service will be activated should not have any resistance towards its implementation, not 
being related to an increase of daily workload. In terms of interest groups to be taken into 
consideration for the implementation of the technology, they are those already considered in 
the communication activity described above.
Discussion and conclusions
The optimized pathway for the diagnosis and management of psoriatic arthritis proposed 
would have a limited organizational impact at both hospital and Regional Health Service 
levels, while leading to theoretical benefits in terms of a prompt diagnosis of the pathology.
Furthermore, the implementation of the multidisciplinary service is in line with the objec-
tives of the resolutions of the Regional Council of Lombardy Region for the “re-organization 
of the management pathway of patients affected with chronic pathologies” [16,17]. The ser-
vice would, in fact, allow the performance of an empowerment activity on patients, concern-
ing their therapeutic and monitoring pathway, giving the possibility to structure an individual 
care plan shared by the two specialists involved (dermatologist and rheumatologist), optimiz-
ing the process.
In terms of health care marketing, the implementation of the service would have a positive 
impact on patients’ experience, improving the quality of the service provided, thanks to the 
multidisciplinary approach adopted, limiting the patients’ resources needed for the diagnosis, 
reducing the number of visits and time loss. The optimized pathway, therefore, would have 
a limited impact on the marketing mix (in terms of typology of service provided, costs for 
patients, setting, and communication activities), while potentially improving patients satisfac-
tion, increasing the possibility of patients’ retention.
The main limit of the analysis conducted is related to its “monocentric” approach and this 
might limit the generalizability of the results. The analysis presented should be considered 
as a preliminary step for a further wider analysis, considering the involvement of different 
stakeholders, as patients, general practitioners, hospital managers, and increasing the number 
of dermatologists and rheumatologists involved.
To successfully implement the dermatological and rheumatologic multidisciplinary ser-
vice, a precise communication strategy is mandatory, as explained above.
At a Regional level, training activities addressed to general practitioners should also be 
promoted to increase their capacity to recognize symptoms that might be related to psoriatic 
arthritis, reducing the time to referral to the multidisciplinary service.
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